SEC Filing Summary: Bioptix, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioptix, Inc. on March 17, 2017, reporting events occurring on March 15 and March 16, 2017. The filing details the closing of a private placement financing transaction. Note: The request metadata referenced "Riot Platforms, Inc.," but the source text explicitly identifies the registrant as Bioptix, Inc.
Key Financial Metrics
- Capital Raised: $4,750,000 in aggregate gross proceeds.
- Instrument Issued: Convertible promissory notes with a principal amount of $4,750,000.
- Warrants Issued: Warrants to purchase an aggregate of 2,800,000 shares of common stock.
- Conversion Price: Notes are convertible at an initial price of $2.50 per share.
- Warrant Exercise Price: $3.56 per share.
- Liquidity Status: Proceeds were deposited into an escrow account with Signature Bank pending a "Qualified Transaction."
Material Changes and Transaction Structure
The Company entered into securities purchase agreements to sell notes and warrants to accredited investors. Key structural terms include:
- Automatic Exchange: Upon filing a Certificate of Designations for "Series A Preferred Stock" (within 45 days of closing), the Notes will automatically exchange for Preferred Shares on a $1.00 to $1.00 basis (principal plus accrued interest).
- Ownership Limitations: Conversion of Notes and exercise of Warrants are capped to prevent any holder from beneficially owning more than 9.99% of outstanding common stock.
- Registration Rights: The Company must file a registration statement within 45 days and obtain effectiveness within 120 days. Failure to do so triggers liquidated damages payable to investors.
- Escrow Arrangements: Both cash proceeds and the securities (Notes, Warrants, and future Preferred Shares) are held in escrow pending the occurrence of a Qualified Transaction.
Outlook, Risks, and Contingencies
- Shareholder Approval: Conversion of Notes and exercise of Warrants are contingent upon NASDAQ approval and shareholder approval of an amendment to the Articles of Incorporation to authorize 15,000,000 shares of "blank check" preferred stock.
- Contingent Liquidity: The availability of the raised capital is restricted as funds remain in escrow until a Qualified Transaction occurs.
- Financial Advisor: Canaccord Genuity, Inc. acted as the financial advisor for the financing.
Investor Verification Checklist
- Verify the definition of "Qualified Transaction" in the Purchase Agreement to understand the conditions required to release escrowed funds.
- Confirm the timeline for the special stockholder meeting to approve the amendment for Series A Preferred Stock.
- Review the liquidated damages clause in the Registration Rights Agreement regarding potential penalties for delayed registration.
- Check for subsequent filings regarding the filing of the Certificate of Designations and the automatic exchange of Notes for Preferred Shares.